# ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

> **NCT04517435** · PHASE1,PHASE2 · TERMINATED · sponsor: **Deepa Jagadeesh** · enrollment: 13 (actual)

## Conditions studied

- Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** ME-401
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT04517435
- **Lead sponsor:** Deepa Jagadeesh
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-28
- **Primary completion:** 2023-05-17
- **Final completion:** 2023-05-17
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Funding unavailable
- **Last updated:** 2025-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04517435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04517435, "ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04517435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*